Verrica Pharmaceuticals

Historical price data

Verrica Pharmaceuticals is a commercial-stage biotech focused on developing and commercializing novel treatments for high-unmet-need skin diseases. Its core achievement is the FDA approval and U.S. launch of YCANTH for molluscum contagiosum, with a Phase 3 program underway for common warts and a Phase 2 asset, VP-315, for basal cell carcinoma. The company's strategy centers on its proprietary topical and intralesional delivery platforms, targeting large patient populations with first-in-class or best-in-class therapeutic options. Recent milestones include a $50 million private placement, a Japanese launch partnership, and key leadership appointments to bolster commercialization.

Proprietary drug-device combination for topical delivery of cantharidin and an intralesional oncolytic peptide platform (VP-315) for immunogenic tumor cell death.

In molluscum, YCANTH holds a first-mover monopoly as the only FDA-approved drug, competing against off-label therapies. For common warts, it would enter a fragmented market with no approved prescription drugs, competing against OTC products and procedures. In BCC, VP-315 faces competition from other non-surgical modalities but has a unique immunogenic mechanism.